Top MarketRank™ StocksTop MarketRank™NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $14.29 -0.23 (-1.58%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$14.15▼$14.6850-Day Range$14.29▼$16.6952-Week Range$14.15▼$32.59Volume1.01 million shsAverage Volume1.70 million shsMarket Capitalization$2.36 billionP/E Ratio79.39Dividend YieldN/APrice Target$25.56Consensus RatingModerate Buy Company OverviewACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More… Musk warns humanity: “Obsolete” (Ad)The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks99th Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 99% of companies evaluated by MarketBeat, and ranked 13th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 11 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth63.46% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 63.46% in the coming year, from $0.52 to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 79.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.00.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 79.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 142.79.Price to Earnings Growth RatioACADIA Pharmaceuticals has a PEG Ratio of 0.49. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.83% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 13.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.83% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 13.54%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.57 News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for ACADIA Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 6 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows5 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $779,494.00 in company stock.Percentage Held by Insiders28.30% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock News HeadlinesBrokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56October 24 at 2:09 AM | americanbankingnews.comDo Options Traders Know Something About Acadia (ACAD) Stock We Don't?October 22 at 7:25 PM | msn.comMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.October 24, 2024 | The Freeport Society (Ad)Leerink Partnrs Issues Positive Estimate for ACAD EarningsOctober 19, 2024 | americanbankingnews.comHealth Canada approves Acadia’s DAYBUE for Rett syndromeOctober 18, 2024 | msn.comAcadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024October 17, 2024 | businesswire.comAcadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett SyndromeOctober 16, 2024 | finance.yahoo.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest UpdateOctober 15, 2024 | americanbankingnews.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of the year. Since then, ACAD shares have decreased by 54.4% and is now trading at $14.29. View the best growth stocks for 2024 here. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. The company's revenue was up 46.4% on a year-over-year basis. Who are ACADIA Pharmaceuticals' major shareholders? Top institutional investors of ACADIA Pharmaceuticals include SG Americas Securities LLC (0.31%), Allspring Global Investments Holdings LLC (0.07%), Hennion & Walsh Asset Management Inc. (0.06%) and Handelsbanken Fonder AB (0.03%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Srdjan R Stankovic, Brendan Teehan, Austin D Kim, Mark C Schneyer, James Kihara and Laura Brege. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/06/2024Today10/23/2024Next Earnings (Confirmed)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year FoundedN/APrice Target and Rating Average Stock Price Target$25.56 High Stock Price Target$42.00 Low Stock Price Target$19.00 Potential Upside/Downside+78.9%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E Ratio79.39 Forward P/E Ratio27.48 P/E Growth0.49Net Income$-61,290,000.00 Net Margins3.43% Pretax Margin5.14% Return on Equity6.89% Return on Assets3.88% Debt Debt-to-Equity RatioN/A Current Ratio2.16 Quick Ratio1.95 Sales & Book Value Annual Sales$890.53 million Price / Sales2.65 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book5.43Miscellaneous Outstanding Shares165,221,000Free Float118,933,000Market Cap$2.36 billion OptionableOptionable Beta0.38 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ACAD) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.